The Most Powerful

Renalytix is an in-vitro diagnostics company aiming to combat the global chronic kidney disease (CKD) crisis, which affects 850 million people worldwide and nearly 40 million in the U.S. Its flagship test, kidneyintelX.dkd, targets CKD in patients with type 2 diabetes.



CKD is underdiagnosed, underassessed, and a major financial burden—costing Medicare $130B annually. While guidelines exist, 80% of patients don’t receive full recommended testing (eGFR + UACR). Further, current testing only confirms disease diagnosis, not its risk for progression.



FDA-approved in June 2023, added to KDIGO guidelines in March 2024, and granted Medicare coverage in June 2024, the test combines proprietary, blood-based biomarkers, kidney function test results from patient health records, and AI to generate a custom report that helps clinical teams understand patient’s level of risk (low, moderate, or high) for progressive decline in kidney function, allowing for earlier and more targeted interventions, and providing the best chance for improving patient’s cardiovascular-kidney-metabolic health.



Renalytix launched THE MOST POWERFUL campaign to raise awareness, promote early kidney health assessment, and highlight the unique 'predictive power' of kidneyintelX.dkd. THE MOST POWERFUL campaign was conceived and all content was created entirely in-house, with just two external freelance resources (designer + web developer). The team created 125 content pieces on a lean $15,150 budget in just 3.5 months. The campaign included print and digital materials, infographics, patient profiles, social content, a 75-page website, and a new physician pitch deck. It focused on storytelling, clinical evidence, and modular assets to suit different formats and time constraints.



Every asset reinforced that this test is a game-changer in predicting risk of chronic kidney disease progression and helping clinicians to personalize treatment plans for their patients according to the risk results.



Results were significant: +261 new ordering clinicians (doubling adoption), +3 new PCP networks (a first for the company), +120% increase in test sales, a Local Coverage Determination from Medicare, LinkedIn campaign impact (+31% follower growth, 3.9M impressions in April 2025 (vs. 0–250 pre-campaign), +274% engagement, 6 posts with 1M+ impressions (vs. 1,200 pre-campaign), website traffic jumped from 200 monthly visits to 1,600 during launch month—an 8x increase.